Lake JG, Weiner LM, Milstone AM, Saiman L, Magill SS, See I. Pathogen distribution and antimicrobial resistance among pediatric healthcare-associated infections reported to the National Healthcare Safety Network, 2011–2014. Infect Control Hosp Epidemiol. 2018;39(1):1–11. https://doi.org/10.1017/ice.2017.236.
Ruth A, McCracken CE, Fortenberry JD, Hall M, Simon HK, Hebbar KB. Pediatric severe sepsis: current trends and outcomes from the Pediatric Health Information Systems database. Pediatr Crit Care Med. 2014;15(9):828–38. https://doi.org/10.1097/PCC.0000000000000254.
Pana ZD, Roilides E, Warris A, Groll AH, Zaoutis T. Epidemiology of invasive fungal disease in children. J Pediatric Infect Dis Soc. 2017;6(suppl_1):S3–11. https://doi.org/10.1093/jpids/pix046.
Article PubMed PubMed Central Google Scholar
Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-50. https://doi.org/10.1093/cid/civ933.
Wynn JL, Tan S, Gantz MG, Das A, Goldberg RN, Adams-Chapman I, et al. Outcomes following candiduria in extremely low birth weight infants. Clin Infect Dis. 2012;54(3):331–9. https://doi.org/10.1093/cid/cir800.
Aliaga S, Clark RH, Laughon M, Walsh TJ, Hope WW, Benjamin DK, et al. Changes in the incidence of candidiasis in neonatal intensive care units. Pediatrics. 2014;133(2):236–42. https://doi.org/10.1542/peds.2013-0671.
Article PubMed PubMed Central Google Scholar
Piqueras AI, Rubio T, Lopez-Medina EM, Gimeno A, Modesto V, Canton E, et al. Recent changes in candidemia trends in a tertiary hospital (2011–2018). Rev Iberoam Micol. 2020;37(3–4):87–93. https://doi.org/10.1016/j.riam.2020.09.005.
Jordan I, Balaguer M, Lopez-Castilla JD, Belda S, Shuffelman C, Garcia-Teresa MA, et al. Per-species risk factors and predictors of invasive Candida infections in patients admitted to pediatric intensive care units: development of ERICAP scoring systems. Pediatr Infect Dis J. 2014;33(8):e187–93. https://doi.org/10.1097/INF.0000000000000274.
Benjamin DK Jr, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;117(1):84–92. https://doi.org/10.1542/peds.2004-2292.
Hope WW, Castagnola E, Groll AH, Roilides E, Akova M, Arendrup MC, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect. 2012;18(Suppl 7):38–52. https://doi.org/10.1111/1469-0691.12040.
CAS Article PubMed Google Scholar
Amphotericin B for injection [package insert]. Big Flats, NY: X-Gen Pharmaceuticals, Inc; 2010.
Stultz JS, Kohinke R, Pakyz AL. Variability in antifungal utilization among neonatal, pediatric, and adult inpatients in academic medical centers throughout the United States of America. BMC Infect Dis. 2018;18(1):501. https://doi.org/10.1186/s12879-018-3410-4.
Article PubMed PubMed Central Google Scholar
Ferreras-Antolin L, Irwin A, Atra A, Dermirjian A, Drysdale SB, Emonts M, et al. Neonatal antifungal consumption is dominated by prophylactic use; outcomes from the pediatric antifungal stewardship: optimizing antifungal prescription study. Pediatr Infect Dis J. 2019;38(12):1219–23. https://doi.org/10.1097/INF.0000000000002463.
Austin N, McGuire W. Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev. 2013;4:CD003850. https://doi.org/10.1002/14651858.CD003850.pub4.
Cleminson J, Austin N, McGuire W. Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev. 2015;10:CD003850. https://doi.org/10.1002/14651858.CD003850.pub5.
Weitkamp JH, Ozdas A, LaFleur B, Potts AL. Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure. J Perinatol. 2008;28(6):405–11. https://doi.org/10.1038/sj.jp.7211914.
CAS Article PubMed Google Scholar
Lee J, Kim HS, Shin SH, Choi CW, Kim EK, Choi EH, et al. Efficacy and safety of fluconazole prophylaxis in extremely low birth weight infants: multicenter pre-post cohort study. BMC Pediatr. 2016;16:67. https://doi.org/10.1186/s12887-016-0605-y.
CAS Article PubMed PubMed Central Google Scholar
Robati Anaraki M, Nouri-Vaskeh M, Abdoli OS. Fluconazole prophylaxis against invasive candidiasis in very low and extremely low birth weight preterm neonates: a systematic review and meta-analysis. Clin Exp Pediatr. 2021;64(4):172–9. https://doi.org/10.3345/cep.2019.01431.
CAS Article PubMed Google Scholar
Leonart LP, Tonin FS, Ferreira VL, Tavares da Silva Penteado S, de Araujo Motta F, Pontarolo R. Fluconazole doses used for prophylaxis of invasive fungal infection in neonatal intensive care units: a network meta-analysis. J Pediatr. 2017;185:129–35 e6. https://doi.org/10.1016/j.jpeds.2017.02.039.
Momper JD, Capparelli EV, Wade KC, Kantak A, Dhanireddy R, Cummings JJ, et al. Population pharmacokinetics of fluconazole in premature infants with birth weights less than 750 grams. Antimicrob Agents Chemother. 2016;60(9):5539–45. https://doi.org/10.1128/AAC.00963-16.
CAS Article PubMed PubMed Central Google Scholar
Wade KC, Benjamin DK Jr, Kaufman DA, Ward RM, Smith PB, Jayaraman B, et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J. 2009;28(8):717–23. https://doi.org/10.1097/INF.0b013e31819f1f50.
Article PubMed PubMed Central Google Scholar
Autmizguine J, Smith BP, Prather K, Bendel C, Natarajan G, Bidegain M, et al. Effect of fluconazole prophylaxis on Candida fluconazole susceptibility in premature infants. J Antimicrob Chemother. 2018;73:3482-87. https://doi.org/10.1093/jac/dky353. This is an important recent study that provides information regarding the impact of fluconazole prophylaixs on Candida fluconazole susceptibility.
Autmizguine J, Tan S, Cohen-Wolkowiez M, Cotten CM, Wiederhold N, Goldberg RN, et al. Antifungal susceptibility and clinical outcome in neonatal candidiasis. Pediatr Infect Dis J. 2018;37(9):923–9. https://doi.org/10.1097/INF.0000000000001913.
Article PubMed PubMed Central Google Scholar
Kirpal H, Gathwala G, Chaudhary U, Sharma D. Prophylactic fluconazole in very low birth weight infants admitted to neonatal intensive care unit: randomized controlled trial. J Matern Fetal Neonatal Med. 2016;29(4):624–8. https://doi.org/10.3109/14767058.2015.1013933.
CAS Article PubMed Google Scholar
Chen IT, Chen CC, Huang HC, Kuo KC. Malassezia furfur emergence and candidemia trends in a neonatal intensive care unit during 10 years: the experience of fluconazole prophylaxis in a single hospital. Adv Neonatal Care. 2020;20(1):E3–8. https://doi.org/10.1097/ANC.0000000000000640.
Driessen M, Ellis JB, Cooper PA, Wainer S, Muwazi F, Hahn D, et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J. 1996;15(12):1107–12. doi: https://doi.org/10.1097/00006454-199612000-00011.
Linder N, Klinger G, Shalit I, Levy I, Ashkenazi S, Haski G, et al. Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J Antimicrob Chemother. 2003;52(4):663–7. https://doi.org/10.1093/jac/dkg419.
CAS Article PubMed Google Scholar
Ascher SB, Smith PB, Watt K, Benjamin DK, Cohen-Wolkowiez M, Clark RH, et al. Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J. 2012;31(5):439–43. https://doi.org/10.1097/INF.0b013e3182467a72.
Article PubMed PubMed Central Google Scholar
Queiroz-Telles F, Berezin E, Leverger G, Freire A, van der Vyver A, Chotpitayasunondh T, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008;27(9):820–6. https://doi.org/10.1097/INF.0b013e31817275e6.
Mohamed WA, Ismail M. A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants. J Trop Pediatr. 2012;58(1):25–30. https://doi.org/10.1093/tropej/fmr025.
Berkow EL, Lockhart SR. Fluconazole resistance in Candida species: a current perspective. Infect Drug Resist. 2017;10:237–45. https://doi.org/10.2147/IDR.S118892.
CAS Article PubMed PubMed Central Google Scholar
Arendrup MC, Patterson TF. Multidrug-resistant candida: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017;216(suppl_3):S445–51. https://doi.org/10.1093/infdis/jix131.
CAS Article PubMed Google Scholar
Mycamine [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2020.
Cancidas [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2019.
Eraxis [package insert]. New York, NY: Pfizer, Inc; 2020.
Benjamin DK, Jr., Kaufman DA, Hope WW, Smith PB, Arrieta A, Manzoni P, et al. A phase 3 study of micafungin versus amphotericin B deoxycholate in infants with invasive candidiasis. Pediatr Infect Dis J. 2018;37(10):992–8. doi: https://doi.org/10.1097/INF.0000000000001996. This is an important recent comparative study, albeit small, potentially supporting micafungin use in neonates and infants for IC.
Kim J, Nakwa FL, Araujo Motta F, Liu H, Dorr MB, Anderson LJ, et al. A randomized, double-blind trial investigating the efficacy of caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neonates and infants younger than 3 months of age. J Antimicrob Chemother. 2020;75(1):215–20. doi: https://doi.org/10.1093/jac/dkz398. This is an important recent comparative study, albeit small, potentially supporting caspofungin use in neonates and infants for IC.
Leverger G, Timsit JF, Milpied N, Gachot B. Use of micafungin for the prevention and treatment of invasive fungal infections in everyday pediatric care in France: results of the MYRIADE study. Pediatr Infect Dis J. 2019;38(7):716–21. https://doi.org/10.1097/INF.0000000000002353.
Zaoutis TE, Prasad PA, Localio AR, Coffin SE, Bell LM, Walsh TJ, et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis. 2010;51(5):e38-45. https://doi.org/10.1086/655698.
Pana ZD, Kotzadamis D, Roilides E. Invasive candidiasis in pediatric intensive care unit: more challenges. Pediatr Infect Dis J. 2018;37(12):1309–11. https://doi.org/10.1097/INF.0000000000002186.
Mantadakis E, Tragiannidis A. Invasive fungal infections in the pediatric intensive care unit. Pediatr Infect Dis J. 2019;38(9):e216–8. https://doi.org/10.1097/INF.0000000000002394.
Milstone AM, Elward A, Song X, Zerr DM, Orscheln R, Speck K, et al. Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster-randomised, crossover trial. Lancet. 2013;381(9872):1099–106. https://doi.org/10.1016/S0140-6736(12)61687-0.
CAS Article PubMed PubMed Central Google Scholar
Xie J, Zhu L, Zhu T, Jian Y, Ding Y, Zhou M, et al. Zinc supplementation reduces Candida infections in pediatric intensive care unit: a randomized placebo-controlled clinical trial. J Clin Biochem Nutr. 2019;64(2):170-3. doi: https://doi.org/10.3164/jcbn.18-74. This study offers some evidence for a non-antifungal based prophylaxis approach in the PICU.
Xie J, Zhu L, Zhu T, Jian Y, Ding Y, Zhou M, et al. Vitamin D-supplemented yogurt drink reduces Candida infections in a paediatric intensive care unit: a randomised, placebo-controlled clinical trial. J Hum Nutr Diet
留言 (0)